HES1 and neoplasm: To examine the synergistic anti-tumor effects of Hes1-cKO and an PD-1 immune checkpoint blockade, we utilized two subcutaneous animal tumor models (TC-1 and MC-38) and administered PD-1 blocking antibody (RMP1-14) by intraperitoneal injection.